GSK (GSK) plans to seek an FDA label update for its leucovorin product as the Trump administration touts the drug's potential ...
The FDA has approved updated labeling for Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for dystrophic epidermolysis bullosa.
Regeneron (REGN) stock is in focus as the FDA approves a label expansion for Evkeeza its cholesterol therapy marketed with Ultragenyx (RARE). Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback